WB
H M R
Endogenous
100
Rabbit
#Q99523
6272
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val361 of human sortilin protein. Antibodies are purified by peptide affinity chromatography.
Background
Sortilin is a multifunctional member of the vacuolar protein sortin-10 (VPS10) receptor family containing type-1 transmembrane proteins that have pleiotropic function in neuronal protein trafficking and viability (1). Sortilin is implicated to have inhibitory effects on tau aggregation in Alzheimer's disease transgenic murine models expressing human mutated tau P301S (2), and also supports to regulate intracellular processing of amyloid precursor proteins (APP) (3,4) and β-secretase, which cleaves APP to produce neurotoxic Aβ peptides (5). Sortilin also plays a role in frontotemporal lobar degeneration (FTLD) by binding and regulating extracellular concentrations of the secreted glycoprotein progranulin (6). Sortilin has been linked to cholesterol circulating concentration and lifetime risk of developing significant atherosclerotic disease. Higher concentrations of sortilin have been found in patients with coronary atherosclerosis (7). Sortilin functions in the immune system within microglia, pro-inflammatory cytokine regulation, phagosome fusion, and pathogen clearance (8).
- Nykjaer, A. and Willnow, T.E. (2012) Trends Neurosci 35, 261-70.
- Johnson, N.R. et al. (2017) Proc Natl Acad Sci U S A 114, E11029-E11036.
- Carlo, A.S. et al. (2013) J Neurosci 33, 358-70.
- Gustafsen, C. et al. (2013) J Neurosci 33, 64-71.
- Finan, G.M. et al. (2011) J Biol Chem 286, 12602-16.
- Hu, F. et al. (2010) Neuron 68, 654-67.
- Biscetti, F. et al. (2019) Cardiovasc Diabetol 18, 5.
- Talbot, H. et al. (2018) Front Pharmacol 9, 1507.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.